TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with limited therapeutic options.
• Pro-tumorigenic inflammation and immunosuppression drive PDAC growth and metastasis.
• Current therapies lack strategies to target cancer-associated inflammation.

Purpose of the Study:

• To investigate the efficacy of intrabody-mediated blockade of Toll-like Receptor (TLR) 2 and TLR9 in human pancreatic cancer cells.
• To assess the impact of targeting TLR2 and TLR9 on inflammatory signaling, proliferation, and apoptosis in PDAC.
• To explore a novel therapeutic strategy for pancreatic cancer by inhibiting intracellular TLR signaling.

Main Methods:

• Development and application of anti-TLR2 and anti-TLR9 specific intrabodies.
• Intracellular targeting of TLR2 and TLR9 within the endoplasmic reticulum (ER) of PDAC cells.
• Analysis of inflammatory signaling (STAT3 phosphorylation), proliferation, and apoptosis (Caspases 3 and 8) markers.

Main Results:

• Intrabody-mediated inhibition of TLR2 and TLR9 effectively suppressed PDAC cell growth.
• Intrabodies accumulated in the ER and interacted with their cognate TLRs.
• Reduced STAT3 phosphorylation and increased Caspase 3 and 8 expression were observed in treated cells.

Conclusions:

• Intrabody-mediated TLR2 and TLR9 inhibition effectively suppresses pancreatic tumor cell growth by blocking inflammatory signaling and proliferation.
• Targeting intracellular TLRs within the ER represents a promising therapeutic intervention for pancreatic cancer.
• This strategy offers a novel approach to combat pro-tumorigenic inflammation in PDAC.